Belgium-based etherna immunotherapies is a biotechnology company specializing in discovery and in addressing challenges for partners developing nucleic acid vaccines and therapeutics. Leveraging over 30 years of experience with RNA technology, etherna supports start-up, early-stage, and late-stage projects with their proprietary platforms across RNA chemistry, LNP formulation, and process technology. The company offers technology and product partnerships, allowing clients to take advantage of etherna's portfolio of intellectual property and expertise, particularly in customizable LNPs, to develop their own pipelines.